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A B S T R A C T
The widespread adoption of the EuroQol 5-dimensional questionnaire
(EQ-5D) has been important for the comparability, transparency, and
consistency of economic evaluations for informing resource allocation
in healthcare. The objectives of this article were to (1) critically assess
whether the widespread adoption of the EQ-5D and its time trade-off
ebased value sets to inform economic evaluation is likely to continue
and (2) speculate about how benefits may be measured and valued to
inform economic evaluation in the future. Evidence supports the use
of the EQ-5D in many areas of health, but there are notable gaps.
Furthermore, there has been interest among some policy makers in
measuring changes in well-being, and in using common outcomes
across sectors. Possibilities for measuring well-being alongside health
can be achieved through bolt-on dimensions or an entirely new
measure capturing both health and well-being. Nevertheless, there
are significant concerns about the logic of estimating a common utility
function. The development of online valuation methods has had a
major impact on the field, which is likely to continue. We, however,
recommend more allowance for respondents to consider their an-
swers. There is an ongoing debate on the role of patient values or
experience-based values. To date, this has seen limited take-up by
decision makers and there are significant technical problems to
obtaining representative and meaningful values. Policy makers and
the general population must decide on the focus and scope of benefits
that are incorporated into economic evaluation, and current evidence
on this is mixed. In part, this will determine whether the widespread
adoption will continue.
Keywords: bolt-on dimensions, capabilities, carer quality of life, eco-
nomic evaluation, experience-based utilities, health-related quality of
life, QALYs, utilities, well-being
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Introduction
Economic evaluation has been used to inform the allocation of
scarce healthcare resources for many years. The most commonly
used technique has been to estimate the incremental cost per
quality-adjusted life-year (QALY) of new health technologies.
QALYs provide a way to capture the benefits of healthcare in
terms of impact on survival and health-related quality of life
(HRQOL). A QALY is generated by multiplying life-years by a
quality adjustment weight or health utility, Q, that is used to
reflect the HRQOL of the person.1 To derive the health utility re-
quires both a description of health and a value of the state of health.
The description is usually generated using self-complete re-
sponses to a questionnaire about health that allow the respondent
to be assigned to a single multidimensional health state. The
value of this health state is estimated to lie on a scale where 1 is
equivalent to full health and 0 is equivalent to being dead, and
values less than 0 indicate that the state of health is worse than
being dead. These values reflect preferences around how good or
bad different health states are; they are used to inform health
technology assessment (HTA) of different health interventions
and are typically elicited frommembers of the general population.
To inform economic evaluation in healthcare, generic
preference-based measures (GPBMs) are most commonly
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recommended by reimbursement agencies to both describe and
value health.2 These measures are generic because they are
intended for use across conditions and treatments and, it is
hoped, to provide consistency and comparability between eco-
nomic evaluations. A GPBM of health has 2 components: a clas-
sification for describing health states and a set of utility values,
called a value set or tariff, for each health state defined by the
classification or a scoring algorithm. Different GPBMs have
different classification systems, meaning that the dimensions of
health, their descriptions, and their severity levels differ across
GPBMs. There are also differences in valuation methods and
protocols, and in the population used to provide the values. For
these reasons, GPBMs generate different utility values (and dif-
ferences in change in utility over time and across treatments)
irrespective of whether there are differences in the health status
of the population.1 This has led to some agencies preferring 1
measure to be used in HTA submissions (eg, National Institute for
Health and Care Excellence [NICE]3 and the Zorginstituut Nederland
[ZIN]4).
The most widely used GPBM is the EuroQol 5-dimensional
questionnaire (EQ-5D).5 This was developed to provide a simple
and easy-to-use measure of HRQOL for administration alongside
disease-specific measures and to provide a measure that could be
readily valued by the general population.6 The EQ-5D describes
health status across 5 dimensionsdmobility, self-care, usual ac-
tivities, pain/discomfort, and anxiety/depressiondand sets of
preference weights that can be applied to convert it into a GPBM.
In response to concerns about the insensitivity of the 3 severity
levels used in the EQ-5D, a 5-level version has been developed.7
The original 3-level version defines 243 states and the new
5-level version defines 3125. These states have been valued using
various valuation techniques. The most widely used in the
context of economic evaluation have been variants of the time
trade-off (TTO) technique across numerous countries and more
recently versions of discrete choice experiments (DCEs). The EQ-
5D can be administered as a patient-reported outcome measure
without scoring responses using the value set, meaning it can be
used outside of applications in economic evaluation (eg, in routine
outcome assessment).
The widespread adoption of the EQ-5D and associated value
sets across different countries is a testament to the vision of the
pioneers who developed it (eg, Brooks and the EuroQol Group6).
But how much longer will the EQ-5D (3- or 5-level version) be the
dominant measure in HTA? It is not in other related sectors such
as social (or personal) care that have used different measures (eg,
The Adult Social Care Outcomes Toolkit (ASCOT)8) and impact on
carers (eg, Carer-Qol9e11 and Carer Experience Scale12). These
measures cover nonhealth domains such as autonomy, social
participation, and meaning. Indeed, outside of healthcare, econ-
omists typically use monetary measures of all relevant benefit.
Even within HTA, the impact of interventions extends beyond
healthcare to other sectors and therefore to nonhealth benefits.
Furthermore, the EQ-5D was never intended to cover all di-
mensions of health, some of which may be important for condi-
tions such as vision, hearing, and some mental health disorders.6
For this reason, the EQ-5Dmay not accurately capture the benefits
of some interventions. This means that different types of mea-
sures sometimes need to be used, which can affect consistency in
resource allocation informed by economic evaluation. There has
also been growing interest in different conceptualizations of
benefit such as well-being and capability13e17 with claims that
they may achieve consistency and capture benefits more relevant
to decision making.16,17
At the same time there have been important developments in
the valuation of the EQ-5D and other measures in the last 2 de-
cades. Much of this has been reviewed in an article by Stolk et al18
in this special issue. In our article we do not address the more
technical issues around the different variants of TTO or DCEs or
how they should be analyzed, but the more broader issues in the
field such as apparently competing approaches to enhance the
role of deliberation compared with the growing use of online data
collection and the role of experience-based or patient values.
The objectives of this article were to (1) critically assess
whether the widespread adoption of the combination of the
EQ-5D and its corresponding TTO-based value sets to inform
economic evaluation is likely to continue and (2) draw on recent
developments in the field to speculate how benefits may be
measured and valued to inform economic evaluation in the
future. Nevertheless, inevitably the article will reflect the interests
of the authors and involve speculation beyond what is known
about future health policy. The article documents the rise to
dominance of the EQ-5D, outlines recent developments in the
scope of what is measured by the classification system and
valuation, and speculates about what the future may bring.
The Rise to Dominance of the EQ-5D
A review of articles published on Web of Science (2004-2010) re-
ported that 63.2% of studies using a GPBM use the EQ-5D, followed
by the Health Utilities Index Mark 3 (9.8%) and the 6-dimensional
health state short form (8.8%).5 How did the EQ-5D come to
dominate economic evaluation? When it came onto the scene in
the early 1990s, most cost-per-QALY studies used the “vignette”
approach, where researchers would construct bespoke de-
scriptions of how health conditions had an impact on the lives of
patients (eg, Sackett and Torrance19). There are major limitations
with using vignettes arising from the poor linkage to evidence and
the lack of comparability between studies. For this reason, re-
searchers welcomed the development of standardized measures
of health that could be completed very simply by the patient and
used to estimate utilities from existing sets of preference weights.
The first to be developed was the Quality of Well-Being Index
and its predecessor the Index of Well-Being.20e22 There are a
number of other GPBMs that have been available for the last 2
decades that can be used in the same way.5 As mentioned earlier,
they have been shown to produce different values on the same
patients and so the choice of measure can have important im-
plications for the final incremental cost effectiveness of an
intervention. One solution to this problem has been the call to
adopt 1 measure as a reference case, but why was the EQ-5D
adopted by NICE and more recently by ZIN in the Netherlands
and appears in a large number of HTA guidelines? One reason
could be evidence of its psychometric performance. Indeed there
is a growing literature on themeasurement properties of GPBMs of
health in different conditions1,23,24 As reviewed elsewhere, the
EQ-5D has been found to perform well in many conditions,
although some problems have been identified in more complex
areas of mental health,25 dementia,26 and sensory conditions.23
Nevertheless, most of the available evidence relies on relatively
crude tests of validity, such as whether they reflect differences
between disease severity groups or changes over time after
treatment. The evidence base is often quite patchy with very little
head-to-head comparison across the measures. A key problem is
the absence of a criterion standard, making it impossible to
demonstrate validity absolutely, but instead weighing up the
strength of evidence supporting a measure. Nonetheless, the EQ-
5D has been shown to performwell in terms ofmany of these tests
of measurement sensitivity in conditions as wide-ranging as type
2 diabetes, cardiovascular disease, and sexual functioning.27e29
The adoption of the EQ-5D may be partly because it was
developed by researchers from many countries with the wide-
spread availability of approved translations, whereas most
other instruments were developed in 1 country (eg, the Quality of
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Well-Being in the United States22, the Health Utilities IndexMark 3
in Canada,30,31 and the 15D in Finland32). Anecdotally, many cli-
nicians suggested that the instrument had face validity and liked
its short format. It has always been free to use for academic
research. These features are not unique to the EQ-5D, and its
widespread adoption is likely to be as much to do with the influ-
ence of the developers as the science per se. A key boost to its
uptake was its adoption in the United Kingdom by NICE for use in
economic evaluation in HTA.3,33,34A number of other key agencies
(eg, ZIN in the Netherlands4) also prefer utility values generated by
the EQ-5D. This and the use of the EQ-5D in many clinical studies
and large surveys become self-fulfilling because consistency with
past evidence is best ensured by using the EQ-5D in any future
study. Nevertheless, will this dominance of the EQ-5D be under-
mined by recent developments in the assessment of benefits?
Recent Developments in Assessing Benefits of
Healthcare
To consider the future use of GPBMs of health, and the EQ-5D in
particular, we will examine recent developments in benefit
assessment in healthcare and their likely implications for the
future of the field including the development of new broader
measures of well-being and capabilities and developments in
valuation.
Going Beyond Health: Well-Being and Capabilities
The EQ-5Dwas not intended to cover all dimensions of health, and
there is some evidence that this results in insensitivity or inap-
propriateness in some patient groups, such as those listed earlier.
Furthermore, it is a measure of health and was not intended to
measure the nonhealth impacts of some healthcare interventions
and nor those of nonhealthcare interventions. The most closely
related sector is social care, which is concerned with meeting the
needs of service users with such things as feeding, clothing,
cleaning, and participation. For social care, palliative care, and the
care of many long-term conditions, the outcomes of care are not
simply improved health per se, but include nonhealth outcomes
such as dignity, autonomy and control, satisfaction with re-
lationships, and having meaningful activities.8 The importance of
social care is expected to grow in developed countries, with the
aging population effectively increasing the number of years peo-
ple spend in ill-health.35 Furthermore, there are important in-
teractions between health and social care with predictions of
greater integration in some countries. These include de-
velopments such as new models of care facilitating integration
across acute, primary, mental, specialist, and social care services
in the United Kingdom.36 There are also important implications
for informal carers, who actually provide much of the social care.
This means that agencies seeking to compare outcomes across
sectors cannot use a sector-specific measure such as the EQ-5D. In
recent years there have been important developments within and
outside health to look at alternatives to health outcomes, and
these have included well-being and capabilities.
Well-being
This raises the issue of what is meant by “well-being.” A broad
conception of well-being is how well an individual’s life is going
on.37 Subjective well-being (SWB) has been described or catego-
rized into 3 types: hedonism (well-being increases when an indi-
vidual experiences more pleasure and/or less pain), flourishing
theories (well-being increases when an individual fulfills their
nature as a human being, or “flourishes”), and life evaluation or
life satisfaction (well-being increases when an individual posi-
tively assesses his or her life).38 Traditionally, there are also
objective list accounts of well-being including items such as lit-
eracy, accommodation, and ability to see.39 There are a number of
tools available to measure SWB, including simple self-reported
items on happiness and life satisfaction, and multi-item mea-
sures of psychological well-being such as the Warwick-Edinburgh
Mental Well-Being Scale.40 Here we focus on the different ap-
proaches to using well-being, rather than a detailed review of the
different measures (for this, see study by Peasgood et al37).
There are 2 lines of argument for using well-being measures.
One is that they might be better able to take into account non-
health dimensions alongside health dimensions.Well-being could
provide an overall indicator of quality of life, which could be used
between health and other sectors and so overcome some of the
limitations of different measures in health and social care.
Another argument for well-being is that the EQ-5D and other
GPBMs use (typically) general population preferences, elicited
using techniques such as TTO where respondents are being asked
to imagine health or social care states. These approaches assume
that individuals are able to predict the likely impact of the health
state being described on their future lives, but this has been
shown not to be the case in health and other contexts.16 General
population respondents usually do not take into account the
extent of any adaptation they may make over time,41 meaning
that their preferences will provide a poor indicator of the actual
impact on their well-being. A more direct description of well-
being might provide a more accurate basis for members of the
general population imagining a state.
The use of well-being measures, particularly SWBmeasures, is
not without its critics. There aremany different measures of SWB,
but none currently provide a basis for estimating QALYs, because
most are not preference-based and none generate values on the
QALY scale. Nevertheless, it might be possible to construct a
classification system on the basis of well-being dimensions and
value it on a QALY scale. Well-being as a concept also has a lack of
agreed definition and little evidence of measurement accuracy. It
has been suggested that “wellbeing policy is running ahead of the
evidence.”42 Policy makers in health and social care wishing to
assess the role of well-being in informing priorities face a number
of uncertainties about the validity and merits of well-being mea-
sures. Psychometric evidence suggests that the items do not seem
to form the constructs originally intended, with little difference
between items intended to tap quite different constructs.43,44 SWB
measures also have been shown to be less sensitive to differences
than the EQ-5D across key health groups.44 Although this is
perhaps not surprising because SWB is a different construct, it has
implications for sample size and for their use in decision making.
The main limitation to using just well-being in healthcare is evi-
dence that many policy makers continue to be interested in
traditional physical health outcomes.37
Capabilities
The notion of SWB is often confused with capabilities, but this
concept has a different genus. It can be attributed to Amartya Sen,
who argued that society is interested with what you can do or be
(ie, capabilities), and not just what you actually choose (or happen)
to do or be (which he calls functioning).45 This addresses the fact
that we may not choose to walk to the shops, but we value the
ability to do so, although he does not seem to suggest that only
capabilities shouldmatter. Sen argues it is not possible to come up
with a list of attributes suitable for all contexts, although there are
important examples, and 1 major attempt is the ICECAP measure.
The 5-item ICECAP-A is similar to GPBMs of health with a multi-
dimensional classification defining capability states valued using
a preference elicitation technique. It aims to measure generic
capabilities that are required to have a high quality of life. ICECAP
is a measure of capabilities for use in both health and social
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care.15,46e48 It has been examined for construct validity49 and test-
retest reliability.50 Initial evidence suggests there may be some
small differences between item wording capturing whether in-
dividuals “can” have key functioning rather than actually “do”
have, although further research is recommended.51
Although it has been used in health and social care and so
could provide a common measure across sectors and the content
is closer to SWB, there are concerns with using capabilities, many
of which are similar to SWB. The valuation method of ICECAP-A
did not include trade-offs between improvements in capabilities
and years of life/survival, and instead assumes that having no
capabilities is equivalent to being dead. This means that it is not
valued on the 1-0 full healthedead scale used to generate QALYs,
and so it is not directly comparable with other instruments
designed to measure QALYs. It is unclear whether ICECAP is
actually consistent with the capability approach because (1) it
seems to suggest that only capability counts, whereas functioning
may still matter to decision makers, and (2) it is not clear whether
it measures a capability “set” because it does not allow for the
natural interdependence between dimensions.13 It has been
shown to be less sensitive than the EQ-5D for many physical
conditions,44 and as for SWB, many decision makers remain
interested in physical outcomes for their own sake.37 This sug-
gests that ICECAP in particular does not fully address the decision
context of HTA.
Ways Forward: Moving Beyond Health?
Decision makers have a broad range of opinions regarding what
outcomes matter and the role of well-being in particular. A study
conducted through focus groups and interviews with members of
the NICE technology appraisal, social care, and public health
committees and members of their citizens’ council found that
“outcomes such as relationships, a sense of control, being able to
do the things you want to, and positive emotion were considered
important aspects of quality of life; current measures, such as EQ-
5D have insufficient content capturing social and emotional
health; that health (including physical functioning) continues to
be important; and decision makers lack the tools necessary to
consistently incorporate wellbeing into decisionmaking (i.e. valid,
well understood measures).”37 There was little support for relying
solely on SWB. One implication is that there is a need for a mea-
sure that captures both health and key aspects of nonehealth-
related quality of life. This can be achieved either by incorporating
additional dimensions into the EQ-5D or by developing a new
measure.
Bolting on missing dimensions
When evidence has suggested that the EQ-5D is unable to capture
change in a specific aspect of health, such as hearing or vision
problems, then there has been research to explore how these
domains could be added to the instrument. Although still at an
exploratory stage, this so-called “bolt-on” research has expanded
significantly in recent years. There has been some exploratory
work on a number of EQ-5D bolt-ons or extra dimensions, but as
yet similar work does not seem to have been undertaken with
other GPBMs of health. Existing areas of bolt-on research include
sleep,52 vision and hearing,23,53 and cognition,54 although not all
bolt-ons seem to have a significant impact on health state values
(eg, sleep). This work could be extended to include some of the
aforementioned well-being dimensions such as autonomy and
control, relationships, and positive emotion.
Nevertheless, bolt-on items have been shown to have an
impact on the coefficients of the 5 original dimensions rather than
being simply additive.23,53 Given there is overlap between health
andwell-being dimensions, particularly withmental health,44 this
then means that any new additional dimension requires a new
preference-based value set. The overlap may raise more funda-
mental concerns about the appropriateness of combining
different concepts such as health and well-being (discussed later).
There are also concerns that bolt-onsmay be developed to capture
the specific benefit of a drug or intervention in an attempt to
maximize a utility gain. More generally, it has the potential to
undermine the generic nature of the EQ-5D and to affect the
comparability of utilities from different disease areas.
Developing a new measure of quality of life
Another approach to moving beyond health would be to develop a
new measure that includes important health dimensions along-
side those linked to well-being. This approach has already been
used in the development of the Assessment of Quality of Life in-
struments by Richardson et al in Australia.55e57 The Assessment
of Quality of Life 8D measures HRQOL in a broader way than do
usual instruments because of the inclusion of 5 psychosocial as-
pects (mental health, happiness, self-worth, relationships, and
coping) alongside health. It is a long instrument (35 items) that
was developed in only 1 country. More evidence regarding its
feasibility in real-life settings is required because it takes rather
longer to complete than the EQ-5D, for example. There is a new
measure that is being developed at the time of writing that aims to
cover health and those aspects of well-being considered impor-
tant by service users.37,58 This international research is looking at
the feasibility and implications of a broadermeasure that is jointly
funded by the UK Medical Research Council and the EuroQol
Group.
This approach raises important concerns. It remains theoret-
ically unclear whether a single measure canmeaningfully capture
health and other quality-of-life considerations into a single clas-
sification system that can be valued alongside each other because
health is an aspect of quality of life and also a facilitator or enabler
of other aspects of quality of life. How will respondents weigh up
dimensions where one is probably causal to another in the same
state being valued? Although this is an issue for measures such as
the EQ-5D, because symptom items such as pain and depression
have implications for usual activities, adding in well-being items
is likely to make this problem more challenging.
Recent Developments in Valuation
There have been major developments in valuation methods, and
this literature is far too large to review here. We will focus on 3
broad developments: the growing use of online computer-based
methods, the use of more deliberative and informed methods,
and “experience-based” utility. Readers interested in the details of
specific methods of elicitation and the many debates between the
methods (eg, TTO vs standard gamble [SG]) are invited to consult
key texts on the subject (eg, studies by Brazier et al1 and Drum-
mond et al59).
Use of Online Samples
Computer-basedmethods for administering preference elicitation
tasks such as TTO and SG have been available for nearly 2 de-
cades, but it is only recently that the real potential of computer-
based methods has started to be realized. A key development
has been the use of online panels that enable quick and
comparatively cheap ways of collecting large samples. There are,
however, concerns about the impact of online methods for the
quality of data. Conventional valuation tasks such as TTO or SG
are unfamiliar and often complex, and evidence suggests that
respondents benefit from having the human contact of an inter-
viewer and even the use of a physical prop.60 Nevertheless, there
has been great interest in recent years in valuation research on
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the use of preference methods such as DCEs and best worse
scaling, which are arguably more feasible to complete online
without an interviewer being present. Furthermore, using DCE
with duration as an additional dimension enables the preference
weights to be placed on the QALY scale. Experimentation and
piloting of valuation methods have become much simpler and
cheaper, which in turn will allow researchers to make more rapid
progress in the development of valuation methods. Nevertheless,
the level of engagement and impact on data quality needs to be
examined rigorously with qualitative and quantitative methods
before they be used to inform decision making.
Experience-Based Utility
Experience-based utility values are when respondents value their
own current health state rather than asking members of the
general public to value hypothetical health states. This approach
does not require people to imagine hypothetical ill-health states
because it asks people about the state they are experiencing
(although they are being asked to imagine full health), and hence
may provide more accurate values of what it is like to live in a
state. Evidence shows that experience-based utility values differ
from hypothetical health state values.61e63 Many reasons may be
attributed to this; for example, patients have a different
perspective and better understanding of the health state because
of the knowledge of actual impact rather than perceived impact
from abstract descriptions (eg, EQ-5D states), and patients may
have adapted to their health state.64 Although it continues to be
explored in published literature, there has been little interest
among policy makers with the notable exception of Sweden.65
Most have been influenced by the argument that because the
general public pays for healthcare through taxation (in many but
not all countries), then arguably it should be their hypothetical
values that set the priorities for the health service rather than
values from patients experiencing the health problems.66
There are important methodological questions surrounding
how to elicit experience-based utilities in a way that could be used
in economic evaluation (see, eg, the study by Brazier et al67). There
are substantial problems with eliciting values from those experi-
encing the statednamely, patientsdmany of whom will be
suffering from severe illness. The general population respondent
is poorly informed about the ill-health state, but then many pa-
tients may have little memory of full health. There are also ethical
issues in asking people in poor states to value their own health by
considering being dead or being fully healthy again. This can have
an impact on the elicitation technique because studies often used
the visual analogue scale to avoid these problems (see, eg, Sun
et al68). It is also unclear whether what they are really valuing in
TTO or the visual analogue scale is consistent with the QALY,
because theymay not be imagining a fixed health state for the rest
of their life, but an unknown lifetime profile of health that will be
dependent on their current condition. Furthermore, those who
respond to a survey in a severe disease, such as advanced cancer
or a severe chronic disease, are unlikely to be representative of
those in their health condition.
Deliberative Approaches
In contrast, with the growing use of online methods, an alterna-
tive approach is the use of methods that allow respondents more
time to reflect on their valuations, consider more evidence (such
as the views of patients about the state, or evidence regarding
adaptation), and/or deliberate with other respondents, friends,
and relatives. Evidence is mixed on whether longer time for
reflection and deliberation alters the values, with some evidence
for change69e71 compared with another study with no change,72
but research into this has been comparatively small-scale. This
could be seen as a proxy for experience-based utility values that
does not suffer from the methodological challenges of collecting
and analyzing experience-based utility data, or a radically
different means to getting the views of society.
Options for obtaining better informed preferences involve
more deliberative techniques including the use of citizens’ jury or
a process similar to multicriteria decision analysis, with a small
sample of participants who become informed during the jury
process through reviewing and examining evidence on the health
state, who then deliberate on health state values and reach
democratic recommendations. Numerical utility values can be
elicited through the use of traditional health state elicitation
techniques such as TTO, or DCE, or thosemore commonly used in
multicriteria decision analysis such as swing weighting, during or
after the deliberation process.67
Deliberative approaches are an important methodological
development, although their uptake in valuing health states is
likely to be limited because of the time it takes and the problems
of standardizing methods given the large range of options.
Conclusions
The widespread adoption of the EQ-5D has been an important
enabler of comparability, transparency, and consistency of
economic evaluations for informing resource allocation in
Table 1 – Moving beyond health to include other aspects of quality of life: pros, cons, and challenges.
Pros Cons Challenges
 The EQ-5D is a measure of health that was
not intended to measure the nonhealth
impacts of healthcare interventions nor the
impact of nonhealthcare interventions
 In social care, palliative care, and the care of
many long-term conditions, outcomes of
healthcare include nonhealth outcomes,
such as dignity
 Enables measurement of all outcomes
occurring from both health and social care
 Enables consistency in resource allocation
decisions across sectors and easier com-
parisons of outcomes across sectors
 Resource allocation decisions and policies
may be informed by the ability of health-
care to have an impact on nonhealth out-
comes, where this may not be their remit
 May not be sensitive to healthcare in-
terventions or to differences across key
health groups
 To inform economic evaluation, a single
measure of utility to generate QALYs is
recommended (rather than 1 measure for
health and 1 for other outcomes)
 It is unclear whether a single measure can
meaningfully capture health and other
quality-of-life considerations into a single
classification system that can be valued
alongside each other
 Health is a facilitator or enabler of other
aspects of quality of life, and the logic of
estimating a common utility function re-
quires careful consideration
QALY indicates quality-adjusted life-year.
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healthcare. Nevertheless, is it a tool that remains fit for purpose,
where that purpose is primarily to measure the benefits for the
patients receiving healthcare technologies? Evidence in health-
care supports the use of the EQ-5D in many areas of health,
although there are some notable gaps because it does not cover all
dimensions of health.
In some countries, economic evaluation is used to cover a
broader range of sectors including public health, social care, and
other nonhealthcare sectors and there is a degree of integration
between them and healthcare (but this may not be relevant to all
countries). In countries where economic evaluation covers
broader sectors, we expect to see that there will be a move to the
use of measures that capture not only health, but also well-being.
Nevertheless, this is not without its challenges, and this is not to
state that measures of only health will not also be used or used
alongside.
Policy makers and the general population must ultimately
make a judgment around the focus and scope of benefits that are
incorporated into economic evaluation. Table 1 provides a sum-
mary of the pros, cons, and challenges associated with moving
beyond health to include other aspects of quality of life. In the
United Kingdom, the picture around the views of policy makers
and the general population is mixed, with some decision makers
favoring the inclusion of nonhealth outcomes related to well-
being such as relationships, control and autonomy, and positive
emotion, but there seems little support for relying solely on these
well-being outcomes. Decision makers and the general public
want to retain more conventional health outcomes such as pain,
mobility, and psychological health in any assessment alongside
any well-being components. Measures should also reflect what
matters to the users of services. Whether consideration of well-
being can be achieved through the addition of bolt-ons or an
entirely new measure capturing both health and well-being re-
mains to be seen. There are significant theoretical concerns about
the way health may be valued in its own right as well as through
well-being, and the logic of estimating a common utility function
needs to be examined.
With the growing proliferation of measures, it might be argued
that a new measure is not what the field needs at the moment.
Without doubt, any newmeasure requires considerable input into
its development and careful psychometric testing and validation
before any potential adoption to inform policy. Nevertheless,
although the development of a new measure provides consider-
able challenges and resources, this should not act as discourage-
ment to the enterprise because no existing measure should be
used simply because it already exists if the scope and focus may
be considered inappropriate for policy or a particular research
question. The marginal benefit of adopting a newmeasure should
be weighed against the loss of consistency.
The development of online valuationmethods has had amajor
impact on the field, and this is likely to continue. Nevertheless, we
would voice a note of caution and recommend that more time be
spent in allowing respondents time to deliberate on their answers
because the numbers will have such an important application in
informing the allocation of scarce resources.
Finally, there has been an ongoing argument on the role of pa-
tient values or experience-based values, andwe expect this debate
to continue. To date, this perspective has seen little take-up by
decision makers and there are significant technical problems to
obtaining representative and meaningful values that reflect just
the health state. We anticipate that the use of experience-based
values may play into an agenda to increase the patient voice, but
the issue is a normative one of whose values should be used to
inform resource allocation in a publicly funded system.
Many decision makers are likely to continue to want to focus
on health and maintain consistency with past decisions. As the
decision of whether and when to adopt the 5-level EQ-5D by NICE
shows, consistency with past decisions is key, and any new
measure, change inwhether themeasure captures beyond health,
or any method of valuation will be subject to far greater scrutiny
than the original 3-level EQ-5D and its value sets.
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